



November 14, 2023

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001  
Scrip Code: 541299

Dear Sir/Madam,

**Sub: Outcome of Board Meeting pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")**

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. the November 14, 2023, which commenced at 05:00 P.M. and concluded at 06:30 P.M. considered and approved, *inter alia*, the following business items:


1. Un-audited standalone financial results of the Company for the half year ended September 30, 2023.

This is for your information and records.

Thanking You  
Yours Faithfully



**Arjan Lal Chandani**  
Managing Director  
DIN: 07014579





# Jain Agarwal & Company

Chartered Accountants

## LIMITED REVIEW REPORT

TO

**THE BOARD OF DIRECTORS OF  
DR LALCHANDANI LABS LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **Dr Lalchandani Labs Limited** ("the Company") for the half year ended 30<sup>th</sup> September 2023 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with Rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Our review is qualified for**

- **Company has not been able to pay installments for few months of term loans/unsecured loans during the period under review. Due to which they have not received the balance confirmation of various lenders. Company has valued the loan at the outstanding amount till the time they have paid the installment of term loans/unsecured loans. So the interest/penal interest levied by the various lenders during the last months of previous financial year and the current period have not been captured in the financial statements. Hence the loss suffered by the company is understated by the aforesaid interest/penal interest.**
- **Gratuity Liability & Leave Encashment Liability is not provided for in the books of accounts of the company and is thus not in accordance with Accounting Standard 15 on "Employee Benefits" issued by the Institute of Chartered Accountants of India.**



### Emphasis of Matter

- During the period under review, the company has defaulted in repayment of principal and interest thereon of term loans and unsecured loans from banks & NBFC's due to which the company has entered into One Time Settlement with six banks/NBFC's and shall be booked the waived amount of loans under the head of Profit from Exceptional Sources. As per the representation received from the management, the Company is in process of getting one-time settlement with other banks/NBFC's for non-payment of installments.
- The company has generally been irregular in deposits of statutory dues viz ESI, PF and TDS for the financial year under consideration.

Our conclusion is not modified in respect of above stated matters.

### Qualified Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Jain Agarwal and Company**  
**(Chartered Accountants)**

Firm's Registration No.: 024866N



**CA Karan Jain**  
**(Partner)**

Membership No.: 521992

Place: New Delhi

Date: 14<sup>th</sup> November 2023

UDIN No.: 23521992BGYSIY1810

DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandaniplab.com/>, Email id: [info@lalchandaniplab.com](mailto:info@lalchandaniplab.com)

Phone: 8010689689/ 8010998844

UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2023

Amount Rs. in Lacs

Sr. No.	Particulars	Half Year Ended			For the Year Ended	Previous Year Ended
		30.09.2023	31.03.2023	30.09.2022	31.03.2023	31.03.2022
		Un-Audited	Audited	Un-Audited	Audited	Audited
I	Revenue from Operations	272.61	275.63	228.39	504.02	1,127.87
II	Other Income	-	-0.19	0.67	0.49	0.08
III	<b>Total Revenue (I+II)</b>	<b>272.61</b>	<b>275.44</b>	<b>229.06</b>	<b>504.51</b>	<b>1,127.95</b>
IV	<b>Expenses</b>					
	(a) Cost of materials consumed	128.20	54.01	67.47	121.48	297.50
	(b) Employee benefits expense	56.23	64.87	80.93	145.80	145.81
	(c) Finance Cost	10.78	50.75	48.06	98.81	53.22
	(d) Depreciation and amortisation expense	32.99	33.64	32.66	66.30	58.77
	(e) Other Expenses	53.22	131.21	97.19	228.40	443.95
	<b>Total Expenses</b>	<b>281.42</b>	<b>334.47</b>	<b>326.32</b>	<b>660.79</b>	<b>999.26</b>
V	Profit before exceptional and extraordinary items and tax (III - IV)	-8.81	-59.02	-97.26	-156.28	128.69
VI	Exceptional Items	-	-	-	-	-
VII	Profit extraordinary items and tax (V - VI)	-8.81	-59.02	-97.26	-156.28	128.69
VIII	Extraordinary Items	-	-	-	-	-
IX	Profit before tax (VIII - IX)	-8.81	-59.02	-97.26	-156.28	128.69
X	Tax Expenses:					
	(1) Current Tax	-	-	-	-	32.79
	(2) Deferred Tax	-	-	-	-	2.57
XI	Profit / (Loss) from Period from continuing operations (VII -VIII)	-8.81	-59.02	-97.26	-156.28	93.33
XII	Profit (Loss) from discontinuing Operations	-	-	-	-	-
XIII	Tax Expense of Discontinuing operations	-	-	-	-	-
XIV	Profit / (Loss) from Discontinuing operations (After Tax XII- XIII)	-	-	-	-	-
XV	Profit (Loss) for the period (XI +XIV)	-8.81	-59.02	-97.26	-156.28	93.33
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)	-	-	-	-	-
	(a) Basic (Rs.)	-0.20	-1.36	-2.24	-3.61	2.15
	(b) Diluted (Rs.)	-0.20	-1.36	-2.24	-3.61	2.15



**Notes:**

1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on 14-11-2023.
2. There were no investor complaints received / pending as at 30th September 2023.
3. The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment-wise reporting is not applicable.
4. The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary.
5. The company has entered into One Time Settlement (OTS scheme) for its unsecured loans with various Banks/NBFC's and the waived loan amount shall be booked as exceptional items in the above Profit/Loss a/c at the time of closure of loan account.
6. In the said board meeting, the company also takes into its records the temporary shutdown of the Punjabi Bagh Lab due to sealing operations carried out by MCD, Delhi.

For Dr Lalchandani Labs Limited,



*(Dr. Arjan Lalchandani)*

*Managing Director (DIN: 07014579)*

*New Delhi*

*14-Nov-2023*

**STANDALONE STATEMENT OF ASSETS AND LIABILITIES**

*Amount in Rs. Lacs*

Sr. No.	Particulars	For the Year Ended	
		30.09.2023	31.03.2023
<b>1</b>	<b>Shareholders' Funds</b>		
	(a) Share Capital	433.31	433.31
	(b) Reserves and Surplus	450.13	458.94
	(c) Money received against share warrants	-	-
	<b>Sub-total-Shareholders' Funds</b>	<b>883.44</b>	<b>892.24</b>
<b>2</b>	<b>Share application money pending allotment</b>		
<b>3</b>	<b>Non-Current Liabilities</b>		
	(a) Long Term Borrowings	309.45	331.74
	(b) Deferred Tax Liability	15.89	15.89
	(c) Other Long-Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	<b>Sub-total-Non-Current Liabilities</b>	<b>325.34</b>	<b>347.62</b>
<b>4</b>	<b>Current Liabilities</b>		
	(a) Short Term Borrowings	319.96	136.61
	(b) Trade Payables	-	-
	(i) Total Outstanding dues of micro enterprises and small enterprises	31.75	59.38
	(ii) Total Outstanding dues of creditors other than micro enterprises and small enterprises	78.06	74.45
	(c) Other Current Liabilities	76.65	261.57
	(d) Short Term Provisions	-	-
	<b>Sub-total-Current Liabilities</b>	<b>506.42</b>	<b>532.01</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,715.19</b>	<b>1,771.88</b>
<b>II</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Fixed Assets		
	(i) Tangible assets	472.92	502.52
	(ii) Intangible assets	33.04	36.67
	(b) Non-Current Investments	24.10	24.10
	(c) Long Term Loans & Advances	106.74	106.74
	(d) Other Non-Current Assets	-	-
	<b>Sub-total-Non-Current Assets</b>	<b>636.80</b>	<b>670.03</b>



<b>2</b>	<b>Current Assets</b>		
	(a) Current Investments	-	-
	(b) Inventories	142.37	152.23
	(c) Trade Receivables	575.30	496.61
	(d) Cash & cash equivalents	240.75	310.24
	(e) Short Term Loans & Advances	33.54	83.68
	(f) Other Current Assets	86.43	59.09
	<b>Sub-total-Current Assets</b>	<b>1,078.39</b>	<b>1,101.85</b>
	<b>TOTAL ASSETS</b>	<b>1,715.19</b>	<b>1,771.88</b>

For Dr Lalchandani Labs Limited



**Dr. Arjan Lalchandani**  
*(Managing Director DIN: 07014579)*

**New Delhi**  
**14-Nov-2023**

## Cash Flow Statement for the Year Ended 30.09.2023

<u>Particulars</u>	<u>AS ON 30.09.2023</u>	<u>F.Y.2022-23</u>
	Amount	Amount
<b>A</b>		
<b><u>Cash Flow from Operating Activities</u></b>		
Net Profit/(Loss) Before Tax	(8.81)	(156.28)
Adjustment For:		
Depreciation	32.99	66.30
Interest Expense	10.78	87.68
Asset Written Off	0.23	0.11
Interest Income	-	(0.49)
<u>Operating Profit Before Working Capital Changes</u>	<u>35.19</u>	<u>(2.68)</u>
 <u>Changes in Working Capital</u>		
Change in Sundry Debtors	(78.69)	(75.10)
Change in Other Current Assets & Non-Current Assets	(27.34)	22.92
Change in Trade Payables	(24.01)	(9.33)
Changes in Inventories	9.86	3.38
Change in Other Current Liabilities	(184.92)	89.76
Short Term Provisions	-	(28.82)
	<u>(305.11)</u>	<u>2.81</u>
 <b><u>Net Cash Flows from Operating Activities(A)</u></b>	 <b><u>(269.91)</u></b>	 <b><u>0.13</u></b>
<b>B</b>		
<b><u>Cash Flow from Investing Activities</u></b>		
Purchase of Fixed Assets	-	(30.48)
Receipts from Loans & Advances	-	14.90
Interest Income	-	0.49
Loans and Advances given	50.14	(4.57)
 <b><u>Net Cash Flow from Investing Activities (B)</u></b>	 <b><u>50.14</u></b>	 <b><u>(19.66)</u></b>
<b>C</b>		
<b><u>Cash Flow from Financing Activities</u></b>		
Long Term Borrowings taken	(22.29)	69.90
Short Term Borrowings	183.35	(5.72)
Interest Paid	(10.78)	(87.67)
 <b><u>Net Cash Flow from Financing Activities (C)</u></b>	 <b><u>150.28</u></b>	 <b><u>(23.49)</u></b>
 <u>Net Change in Cash (A+B+C)</u>	 (69.49)	 (43.03)
<b>Cash and Cash Equivalents at the Beginning of Year</b>	<b>310.24</b>	<b>353.27</b>
<b>Cash and Cash Equivalents at the End of Year</b>	<b><u>240.75</u></b>	<b><u>310.24</u></b>

For Dr Lalchandani Labs Limited



Dr. Arjan Lalchandani  
 (Managing Director DIN: 07014579)  
 New Delhi  
 14-Nov-2023